Silexion Therapeutics Ltd.
SLXN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $7 | $112 | $279 |
| - Cash | $9 | $3 | $6 | $1 |
| + Debt | $0 | $4 | $3 | $4 |
| Enterprise Value | – | $7 | $109 | $282 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$2 | -$2 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$3 | -$2 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | 2.88 | 4.32 | -0.26 | -0.19 |
| % Growth | -33.3% | 1,761.5% | -36.8% | – |
| Operating Cash Flow | -$3 | -$3 | -$2 | -$3 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$3 | -$3 | -$2 | -$3 |